Um tipo de câncer que começa nos canais biliares dentro do fígado (chamado colangiocarcinoma intra-hepático) ou na área onde os canais biliares direito e esquerdo do fígado se juntam, ou perto dela (colangiocarcinoma hilar). A olho nu, essas lesões de câncer são sólidas, parecem caroços e têm uma cor acinzentada. Ao microscópio, a grande maioria dos casos são adenocarcinomas. Os sinais e sintomas incluem mal-estar, perda de peso, dor na parte superior direita do abdômen e suores noturnos. A detecção precoce é difícil e o prognóstico geralmente não é bom.
Introdução
O que você precisa saber de cara
Um tipo de câncer que começa nos canais biliares dentro do fígado (chamado colangiocarcinoma intra-hepático) ou na área onde os canais biliares direito e esquerdo do fígado se juntam, ou perto dela (colangiocarcinoma hilar). A olho nu, essas lesões de câncer são sólidas, parecem caroços e têm uma cor acinzentada. Ao microscópio, a grande maioria dos casos são adenocarcinomas. Os sinais e sintomas incluem mal-estar, perda de peso, dor na parte superior direita do abdômen e suores noturnos. A detecção precoce é difícil e o prognóstico geralmente não é bom.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 6 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 14 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
4 genes identificados com associação a esta condição. Padrão de herança: Not applicable.
Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1. Upon endogenous stimulation by NELL2, ROS1 activates the intracellular signaling pathway and triggers epididymal epithelial differentiation and subsequent sperm maturation (By similarity). May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including
Cell membrane
May act at junctions between the membrane and the cytoskeleton. Possesses tyrosine phosphatase activity
Cell membraneCytoplasm, cytoskeleton
E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage (PubMed:10500182, PubMed:12887909, PubMed:12890688, PubMed:14976165, PubMed:16818604, PubMed:17525340, PubMed:19261748). It is unclear whether it also mediates the formation of other types of polyubiquitin chains (PubMed:12890688). The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular path
NucleusChromosomeCytoplasm
Breast cancer
A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May
NucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosome
Breast cancer
A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Medicamentos aprovados (FDA)
2 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
32,869 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
36 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Colangiocarcinoma
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
16 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
1.037 ensaios clínicos encontrados, 28 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 15.359
Notch signaling in liver diseases: mechanistic insights and therapeutic implications.
The Notch signaling pathway represents an evolutionarily conserved mechanism of intercellular communication that plays critical roles in organ development and tissue homeostasis. However, its functions in liver physiology and pathology demonstrate remarkable context-dependent characteristics, with dysregulated signaling contributing to various liver disorders. This review systematically summarizes the complex roles of Notch signaling in liver health and disease. It comprehensively examines the pathway's essential functions in biliary development, hepatic regeneration, and metabolic homeostasis, while providing a detailed analysis of its pathogenic mechanisms in conditions including Alagille syndrome, drug-induced liver injury, non-alcoholic fatty liver disease, liver fibrosis, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. Our review particularly emphasizes the dual function of Notch signaling in hepatobiliary malignancies, where it can exert either oncogenic or tumor-suppressive effects depending on specific cellular contexts, molecular interactions, and microenvironmental cues. Furthermore, we highlight the evolution of therapeutic strategies from broad-spectrum γ-secretase inhibitors to more precise approaches involving ligand-specific antibodies, transcriptional complex blockers, and pathway agonists, while addressing persistent challenges in clinical translation including on-target toxicities, compensatory resistance mechanisms, and context-dependent responses. Looking forward, this review outlines promising research directions featuring biomarker-guided patient stratification, rational combination therapies with immune checkpoint inhibitors, and spatiotemporally precise regulatory strategies. By integrating foundational knowledge with recent advances, this work provides valuable insights for understanding Notch signaling's complex roles in liver pathophysiology and for developing novel therapeutic interventions.
Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment.
Most patients with intrahepatic cholangiocarcinoma (ICC) present with advanced, unresectable disease. Although gemcitabine-cisplatin (GC) plus durvalumab improves outcomes, its real-world potential for conversion to curative resection and the associated tumor microenvironment (TME) changes remain unclear. In this prospective single-center study, 66 patients with advanced, initially unresectable ICC, were enrolled; 55 patients were evaluable. Patients received GC plus durvalumab. The primary endpoints were overall survival (OS), conversion success rate, and R0 resection rate. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Tumor response was assessed per RECIST v1.1. Landmark analyses evaluated OS by early objective response (CR/PR vs SD/PD at first assessment) and conversion surgery status. RNA sequencing and immunofluorescence were performed to explore molecular correlates of response. Among 66 enrolled patients, 46 (69.7%) had locally advanced and 20 (30.3%) had metastatic disease at baseline. Median OS was 13.0 months (95% CI, 9.97-15.8) and median PFS was 9.33 months (95% CI, 7.47-13.53). ORR and DCR were 27.3% and 65.2%, respectively. Ten patients (15.2%) achieved R0 resection after meeting predefined criteria for conversion surgery. Early CR/PR was associated with significantly longer OS, and, among the 18 patients who became eligible for surgery, those who underwent R0 resection had numerically longer OS than surgery-eligible patients who continued systemic therapy alone. Transcriptomics identified 135 DEGs between responders and non-responders, enriched in immune-regulatory and mesenchymal pathways. Immunofluorescence confirmed increased PD-L1 expression and CD8⁺ T-cell infiltration with reduced α-SMA after treatment. GC plus durvalumab showed encouraging efficacy with acceptable safety in advanced ICC and enabled R0 resection in a subset of patients. Immune activation and stromal remodeling may underlie treatment sensitivity, supporting TME-informed precision conversion strategies that warrant validation in larger multicenter cohorts. This is the first prospective single-center study to evaluate gemcitabine-cisplatin (GC) plus durvalumab for conversion therapy in advanced intrahepatic cholangiocarcinoma (ICC), providing real-world evidence for resectability improvement. GC plus durvalumab achieved a median OS of 13.0 months and a 15.2% R0 resection rate, outperforming historical GC monotherapy and aligning with TOPAZ-1 outcomes in ICC-specific populations, while landmark analyses showed that early radiologic response and conversion surgery were both associated with superior overall survival. Transcriptomic and immunofluorescence analyses identified TME remodeling (↑CD8⁺T cells, ↓α-SMA) and γδT cell infiltration as potential mechanisms of response, offering novel biomarkers for precision conversion therapy. The regimen showed favorable safety with no treatment-related deaths, supporting its feasibility in advanced ICC patients eligible for curative-intent surgery.
Artificial Intelligence in hepatology: A position paper by the Italian Association for the Study of the Liver.
Artificial Intelligence (AI) is transforming medicine, providing unprecedented opportunities to enhance diagnosis, prognosis, and treatment across all areas of hepatology. This Position Paper by the Italian Association for the Study of the Liver (AISF) offers a comprehensive overview of the current and emerging roles of AI in liver diseases, highlighting both its promise and its limitations. The document critically examines methodological, ethical, and educational challenges associated with AI integration in clinical and research settings, and reviews key applications in MASLD/MASH, alcohol-related liver disease, autoimmune and cholestatic liver diseases, viral hepatitis, drug-induced liver injury, hepatocellular carcinoma, cholangiocarcinoma, and liver transplantation. Particular emphasis is placed on data quality, algorithmic fairness, explainability, and reproducibility, as well as on the necessity of robust external validation and adherence to international reporting standards (TRIPOD-AI, CONSORT-AI, DECIDE-AI, CHAMAI and others). The AISF advocates a responsible and evidence-based adoption of AI through multidisciplinary collaboration, professional education, and patient engagement. This Position Paper outlines a national roadmap to align AI innovation with ethics, transparency, and equity, ensuring that AI becomes a genuine ally of hepatology and patient-centered care.
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.
Intrahepatic cholangiocarcinoma (ICC) features poor survival due to frequent recurrences and limited prognostic markers. Using mass spectrometry-based proteomics, we analyze two independent cohorts comprising 80 and 62 treatment-naive ICC tumors, along with 9 independent patient-derived xenografts (PDX). In the first cohort, we identify two subclusters with distinct times-to-recurrence (TTR): An extracellular matrix (ECM)-enriched cluster (mean TTR 859 days) and a proliferation cluster (mean TTR 229 days). A 4-protein classifier trained on our cohort accurately stratifies these clusters in the Dong et al. dataset (2022) and in our second cohort, revealing similar proteomic motifs and clinical outcomes. The translation regulator EIF4A1, enriched in ICCs of both clusters, emerges as a therapeutic target, as its inhibition with eFT226 significantly reduces tumor growth in an ICC PDX model. Proteomic analyses of various PDX models also emphasize the critical role of tumor-stroma interactions in ICC. Overall, this study establishes two prognostic proteomic clusters, validates their relevance across datasets, and highlights EIF4A1 inhibition as a potential therapeutic strategy.
The evolving role of futibatinib for advanced cholangiocarcinoma.
Cholangiocarcinoma (CCA) continues to be classified as a rare cancer with high mortality rates, underscoring the urgent need for more effective systemic treatment strategies. The widespread implementation of next-generation sequencing has enabled comprehensive characterization of the genomic landscape of CCA, revealing a relatively high prevalence of actionable genetic alterations. In this evolving therapeutic context, futibatinib has gained attention as a selective, irreversible pan-fibroblast growth factor receptor (FGFR) inhibitor that covalently binds to the FGFR kinase domain, thereby maintaining inhibitory activity against a broad spectrum of FGFR2 resistance mutations. This distinct mechanism of action represents a significant advancement over earlier reversible inhibitors and provides a strong biological rationale for its use in patients with FGFR2-altered CCA. A comprehensive literature search was performed in PubMed/MEDLINE, Embase, and Scopus for studies published from January 2000 to February 2026, using combinations of the terms 'cholangiocarcinoma,' 'FGFR2,' 'fibroblast growth factor receptor,' and 'futibatinib.' Relevant clinical trials, translational studies, and review articles were screened for inclusion. Futibatinib represents the most biologically rational FGFR inhibitor currently available for FGFR2-altered CCA, as it directly addresses the dominant mechanism limiting the efficacy of earlier agent, on-target resistance driven by secondary FGFR2 kinase domain mutations.
Publicações recentes
Curative resection of borderline resectable perihilar cholangiocarcinoma following neoadjuvant gemcitabine and cisplatin plus durvalumab immunochemotherapy: a case report.
Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma.
Prospective Head-to-Head Comparison of Fibroblast Imaging with [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]FDG PET/CT in Unclear Hepatic Lesions.
Lymph node dissection in intrahepatic cholangiocarcinoma: Cutting through heterogeneity to reveal the survival signal of an adequate dissection.
[Differential diagnostics of inflammatory changes and epithelial neoplasia of extrahepatic bile ducts].
📚 EuropePMC14.360 artigos no totalmostrando 197
Notch signaling in liver diseases: mechanistic insights and therapeutic implications.
Frontiers in cell and developmental biologyGemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment.
Hepatology internationalArtificial Intelligence in hepatology: A position paper by the Italian Association for the Study of the Liver.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverImpact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma.
Biochemical pharmacologyDiffusion-derived "Vessel Density" (DDVD) and Slow Diffusion Coefficient (SDC) Signal Features of Mass-forming Intrahepatic Cholangiocarcinoma Compared to Those of Hepatocellular Carcinoma and Liver Metastases: Preliminary Results.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der NuklearmedizinIntegrating Circulating Tumor DNA (ctDNA) Into Postoperative Surveillance After the Resection of Intrahepatic Cholangiocarcinoma: A Proposed Hybrid Imaging-Molecular Framework.
CureusProteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.
Nature communicationsBiologic stratification with tumor burden score and CA19-9 to inform vascular resection in intrahepatic cholangiocarcinoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyClinical implications of an intraoperative margin-positive distal bile duct in perihilar cholangiocarcinoma: international multicentre cohort study.
BJS openThe evolving role of futibatinib for advanced cholangiocarcinoma.
Expert review of gastroenterology & hepatologySaikosaponin D Induced Apoptosis and Anti-Tumor Effect Enhancing Chemotherapy Sensitivity of Gemcitabine in Patient-Derived Cholangiocarcinoma Organoids.
Cancer management and researchCholangiocarcinoma: Is Preoperative Histologic Confirmation Mandatory Before Major Hepatobiliary Surgery?
CureusTREM2 inhibits cholangiocarcinoma progression by regulating the TGF-β/Smad2/3 signaling pathway.
American journal of cancer researchSerum Lipid-Based Prognostic Model for Advanced Intrahepatic Cholangiocarcinoma Under Chemo-Immunotherapy.
Journal of hepatocellular carcinomaCase Report: Spontaneous Tumor Lysis Syndrome in a Patient With Cholangiocarcinoma.
Journal of investigative medicine high impact case reportsMenopausal hormone therapy and risk of liver cancer in a swedish population-based cohort study.
Journal of the National Cancer InstituteMolecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.
Journal of hepatologyCorrigendum to "Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role" [BBA Mol. Cell Res. 1873 (2026) 120081].
Biochimica et biophysica acta. Molecular cell researchAtypical Ductular Reactions Are a Distinct Regenerative Phenomenon in Hepatocellular Carcinoma (HCC) Patients after Transarterial Chemoembolization.
Laboratory investigation; a journal of technical methods and pathologyLiver transplantation in unresectable intrahepatic cholangiocarcinoma following neoadjuvant chemotherapy and SIRT.
JHEP reports : innovation in hepatologyPerineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis.
JHEP reports : innovation in hepatologyIntegrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma.
Biomedical reportsMolecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma.
GutThe rationale against a "mandatory" extended hepatectomy in perihilar cholangiocarcinoma: meta-analysis.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyLipidomic analysis of bile from patients with extrahepatic cholangiocarcinoma.
PloS oneRetroperitoneal-First Laparoscopic Approach (Retlap) for Bile Duct Resection in Pancreaticobiliary Maljunction (PBM): A Novel and Reasonable Approach to Intrapancreatic Bile Duct.
Annals of surgical oncologyPODXL2 Promotes Cholangiocarcinoma Progression via Interactions with Ezrin and Activation of the MAPK/ERK1/2 and PI3K/AKT Signaling Pathways.
Digestive diseases and sciencesImaging tumor microenvironment: clinical experience with 68Ga-FAPI PET/CT across multiple cancer types.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...Impact of combined vascular resection on short and long-term results following radical surgery for hilar cholangiocarcinoma: evidence from a systematic assessment.
World journal of surgical oncologyNeoadjuvant GOLP is effective in high-risk intrahepatic cholangiocarcinoma.
Nature reviews. Clinical oncologyComprehensive molecular-clinical profiling of cholangiocarcinoma according to pathologic subtypes.
HPB : the official journal of the International Hepato Pancreato Biliary AssociationCombined Hepatocellular-Cholangiocarcinoma Patient Treated with Durvalumab Plus Gemcitabine and Cisplatin: A Case Report.
Internal medicine (Tokyo, Japan)Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.
ESMO openPredicting recurrence in patients with node-negative perihilar cholangiocarcinoma after an R0 resection.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyThe role of mesencephalic astrocyte-derived neurotrophic factor in digestive diseases.
Annals of medicineInactivating LATS2 Variation Drives Tumor Progression and Resistance to Anti-PD-1 Therapy in Intrahepatic Cholangiocarcinoma.
Clinical and molecular hepatologyMri-based Ki-67 prediction for intrahepatic cholangiocarcinoma: Risk stratification and treatment efficacy prediction.
European journal of radiologyASO Visual Abstract: Impact of Additional Resection on Outcomes in Patients with Positive Proximal Margin of Perihilar Cholangiocarcinoma - A Systematic Review and Network Meta-analysis.
Annals of surgical oncologyThe allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1.
The Journal of clinical investigationAURKB drives aggressive phenotype and clinicopathological progression in cholangiocarcinoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoSingle-cell and bulk transcriptomic analyses uncover immune subtypes associated with programmed cell death features in intrahepatic cholangiocarcinoma.
Scientific reportsTargeting MUC16 suppresses malignant progression and chemoresistance in large-duct type intrahepatic cholangiocarcinoma.
Cancer lettersTranscriptional co-activators YAP/TAZ in cancer-associated fibroblasts are dispensable for Notch-driven intrahepatic cholangiocarcinoma.
Journal of molecular cell biologyDiagnostic Performance Comparison of AFP, PIVKA-II, GALAD Model, and ASAP Model Across Two Chemiluminescence Immunoassay Platforms for Hepatocellular Carcinoma.
Journal of hepatocellular carcinomaA novel technique of spacer implantation and proton beam therapy for hilar cholangiocarcinoma: a case report.
Frontiers in oncologyPortal vein reconstruction reduces textbook outcome achievement following radical resection for hilar cholangiocarcinoma.
Frontiers in oncologyPercutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma.
Academic radiologyProton beam therapy versus photon therapy for multiple malignancies: An umbrella systematic review and meta-analysis.
Critical reviews in oncology/hematologyPERSoN4: A Multiparametric Ultrasound Model to Improve CEUS LI-RADS for HCC.
JHEP reports : innovation in hepatologyLirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cells.
Drug metabolism and disposition: the biological fate of chemicalsRole of Endoscopy in Malignant Biliary Obstruction.
Diagnostics (Basel, Switzerland)Pancreatic Head Cancer Masquerading as Distal Cholangiocarcinoma: Diagnostic Challenges, Tumor Characteristics, and Oncologic Outcomes.
CancersEvaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation.
JHEP reports : innovation in hepatologySingle-photon emission computed tomography functional liver imaging to facilitate reirradiation for liver malignancies: A phase I trial.
JHEP reports : innovation in hepatologyAMBP gene activation promotes cholangiocarcinoma progression through the WNT/β-catenin signaling pathway: Regulatory effect of polysaccharides from Auricularia auricula-judae.
MedicineDiagnostic challenges in biliary cytology of biliary inflammatory pseudotumor of the liver: A case report and a review of the literature.
Medicine internationalMulticohort Validation of Gut Microbiome Signatures for Cholangiocarcinoma Diagnosis and Functional Characterization of Bifidobacterium Pseudocatenulatum.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.
Liver international : official journal of the International Association for the Study of the LiverShort- and long-term outcomes after laparoscopic and open liver resection for combined hepatocellular-cholangiocarcinoma patients: a propensity score-matched study.
Journal of gastrointestinal oncologySeparation of liver focal nodular hyperplasia (FNH) and liver malignant tumors by a combination of T2-weighted imaging signal and three diffusion magnetic resonance metrics of diffusion-derived vessel density, slow diffusion coefficient, and apparent diffusion coefficient.
Journal of gastrointestinal oncologyA compass in the challenge: the CALLY index as a prognostic biomarker in advanced cholangiocarcinoma treated with chemoimmunotherapy: a retrospective propensity score-matched cohort study.
Frontiers in immunologyDevelopment, Expansion, and Histological Characterization of Patient-Derived Liver Organoids for Drug Screening and Disease Modeling.
Bio-protocolEfficacy of transarterial chemoembolization combined with PD-1 versus PD-L1 inhibitors in mass-forming intrahepatic cholangiocarcinoma: a multicenter retrospective study.
Translational cancer researchClinical efficacy of HAIC combined with TACE in patients with unresectable intrahepatic cholangiocarcinoma.
BMC cancerValue of Imaging Parameters of [18F]FDG PET/CT and Serological Indices in Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma.
Molecular imaging and biologyPhytochemical profile and chemosensitizing anticancer activity of Mitragyna speciosa and mitragynine.
Scientific reportsA deceptively benign biliary lesion revealing an ALK-rearranged intrahepatic cholangiocarcinoma.
HistopathologyDoes calculating the textbook outcome based on its negative predictors enhance the transparency of intrahepatic cholangiocarcinoma surgery assessment?
Annals of hepato-biliary-pancreatic surgeryThe prognostic value analysis of PIV, PLR, LMR, NPR, and NLR in hilar cholangiocarcinoma.
BMC cancerCombined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective.
Journal of liver cancerFocal "Targetoid" liver lesions on MRI: a diagnostic and practical imaging approach.
Abdominal radiology (New York)Diffusion kurtosis imaging in predicting pathological grade of intrahepatic cholangiocarcinoma: a preliminary study.
Abdominal radiology (New York)Immunotherapy impact of macrophage glycosylation on cholangiocarcinoma and its prognostic and immune microenvironment significance.
Human vaccines & immunotherapeuticsGlucosamine induces apoptosis of cholangiocarcinoma cells by suppressing high-mannose type N-glycosylation and EGFR/STAT3 signaling.
Future science OAMYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1.
International journal of biological sciencesPrognostic implications of tumour number in intrahepatic cholangiocarcinoma.
JHEP reports : innovation in hepatologyIntegrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.
International journal of medical sciencesGlobo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway.
TheranosticsLeft Ventricular Apical Intracardiac Mass With Embolic Stroke During Aggregatibacter segnis Bacteremia Following Acute Cholangitis: A Case Report.
CureusFunctional characterization of BAP1 mutations in genome edited cholangiocarcinoma organoids: Role in cell death and drug responses.
iScienceEpidemiology, biomarkers, and therapeutic approach in early-stage biliary tract cancers.
Chinese clinical oncologyRadiological Loco-Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature.
Liver international : official journal of the International Association for the Study of the LiverTransplant hepatology: New epidemiology and indications.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverDifferences in Right Hepatic Duct Length Among Left-Sided Hepatectomies: Conventional Hepatectomy Versus Extended Hepatectomy Versus Trisectionectomy.
Journal of hepato-biliary-pancreatic sciences3Es-Based Program to Enhance Safety Behaviors Among Fermented Fish Producers in Northeast Thailand: Implications for Liver Fluke and Cholangiocarcinoma Prevention.
Asian Pacific journal of cancer prevention : APJCPThe Predictors of Liver Fluke Infection-Preventive Behaviors, Khon Kaen Province: A Structural Equation Model.
Asian Pacific journal of cancer prevention : APJCPA confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma.
Annals of oncology : official journal of the European Society for Medical OncologyDistinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression: Roles of AKT and YAP during iCCA.
Journal of hepatologyElevated Creatine Kinase as a Marker for Aggressive GI Malignancy.
Journal of community hospital internal medicine perspectivesL-lactate-driven PSMD14 lactylation and stabilization promote lactate production and ferroptosis resistance via ENO1 in intrahepatic cholangiocarcinoma.
Cancer lettersThe role of radiotherapy in the management of combined hepatocellular-cholangiocarcinoma: current evidence and future perspectives.
Journal of liver cancerImaging differentiation of hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, and intrahepatic cholangiocarcinoma: pitfalls and advances.
Journal of liver cancerContemporary overview of liver transplantation for intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.
Journal of liver cancerSystemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.
Journal of liver cancer[Mechanism of miR-199a-5p prevents migration and invasion of cholangiocarcinoma by targeting hypoxia-inducible factor 1α].
Zhonghua yi xue za zhiETV4 lysine 2-hydroxyisobutyrylation promotes intrahepatic cholangiocarcinoma progression by suppressing ferroptosis through TXNIP downregulation.
Cancer lettersNeoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
The New England journal of medicineLow-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma.
Hepatology (Baltimore, Md.)Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.
Journal of drugs in dermatology : JDDLong-term survival after multidisciplinary treatment including durvalumab for recurrent perihilar cholangiocarcinoma.
Clinical journal of gastroenterologyVEGF-Positive Mass-Forming Intrahepatic Cholangiocarcinoma: New Subtype Based on Radiological and Molecular Pathological Analysis.
Hepatology research : the official journal of the Japan Society of HepatologyFish-borne trematode metacercarial infections as bioindicators for heavy-metal contamination in cyprinoid fish from Northeastern Thailand.
Food and waterborne parasitologym6A-dependent translation of circPICALM encodes a novel metastasis-promoting oncoprotein in intrahepatic cholangiocarcinoma.
Molecular cancerPerioperative approaches for patients with biliary tract cancer.
Nature reviews. Clinical oncologyASO Author Reflections: Reassessing the Value of Additional Proximal Margin Resection for Perihilar Cholangiocarcinoma.
Annals of surgical oncologyUHPLC-QTOF-MS/MS-based metabolomic discovery of anticancer compounds in ethanolic extracts of Ficus hispida L. f.
PloS oneThe value of gadobenate dimeglumine-enhanced MRI quantification in predicting aggressiveness and prognosis of typical intrahepatic mass-forming cholangiocarcinoma: a multicenter retrospective study.
Insights into imagingMRI features and LI-RADS categorization of combined hepatocellular-cholangiocarcinoma: a scoping review with prognostic implications.
La Radiologia medicaFibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.
Drug design, development and therapyFocal Hepatic Steatosis Mimicking a Hilar Tumor With Rapid Resolution After Glycemic Control: A Case Report.
Cureus[Efficacy of photodynamic therapy in extrahepatic cholangiocarcinoma].
Zhonghua wai ke za zhi [Chinese journal of surgery][Development of an early diagnostic model for intrahepatic cholangiocarcinoma based on serum peptidomics].
Zhonghua wai ke za zhi [Chinese journal of surgery][Risk factors and prognostic value of lymph node metastasis in patients undergoing curative resection for intrahepatic cholangiocarcinoma].
Zhonghua wai ke za zhi [Chinese journal of surgery][Effect of conversion therapy and prognostic factors in patients with advanced intrahepatic cholangiocarcinoma: a real-world study].
Zhonghua wai ke za zhi [Chinese journal of surgery][Development and validation of a preoperative prediction model for very early recurrence after radical resection of intrahepatic mass-forming cholangiocarcinoma].
Zhonghua wai ke za zhi [Chinese journal of surgery][The value and controversy of hepatopancreatoduodenectomy in the treatment of cholangiocarcinoma].
Zhonghua wai ke za zhi [Chinese journal of surgery][Technical points of portal vein resection and reconstruction for perihilar cholangiocarcinoma: based on the experience of Nagoya University Hospital].
Zhonghua wai ke za zhi [Chinese journal of surgery]Opening the Flood Gates: Epigenetic Regulators Safeguard Against Rogue Lineage Plasticity in Cholangiocarcinoma.
Cellular and molecular gastroenterology and hepatologyMolecular Profiling of Cholangiocarcinoma Predicts Outcomes Post-Liver Transplantation.
JCO precision oncologyIntraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma.
Journal of visualized experiments : JoVERobotic-Assisted Radical Resection for Hilar Cholangiocarcinoma.
Journal of visualized experiments : JoVECholangiolocellular Component Predicts a Biologically Distinct Subgroup of Mass-Forming Intrahepatic Cholangiocarcinoma.
Cancer scienceProlonged Radiation-Induced Gastritis Following Yttrium-90 Radioembolization: A Case of Persistent Dyspepsia and Endoscopic Surveillance.
CureusOccurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis.
PeerJHighly suspected fulminant myocarditis induced by the immune checkpoint inhibitor tislelizumab: a case report with third-degree atrioventricular block and recurrent ventricular tachycardia.
Frontiers in cardiovascular medicineComprehensive identification of microbial and metabolomic factors impacting ICC recurrence.
Frontiers in oncologyBiliary pseudotumor with lobar hepatic atrophy mimicking intrahepatic mass-forming cholangiocarcinoma.
Diagnostic and interventional imagingConditional survival after curative resection for extrahepatic cholangiocarcinoma: a comprehensive analysis of overall, recurrence-free, and relative survival.
HPB : the official journal of the International Hepato Pancreato Biliary Association[Epidemiology, carcinogenicity, prevention and control of clonorchiasis in China].
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhiAcquired bisalbuminemia associated with hepatobiliary disease: a two-case report and diagnostic implications.
Laboratory medicineDiverse Biological Functions of IGF2BPs in Hepatobiliary Cancers and Their Clinical Relevance.
Frontiers in bioscience (Landmark edition)Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.
Cancer reports (Hoboken, N.J.)Adenosine Inhibits Cholangiocarcinoma by a Concurrent Activation of AMPK and mTORC1 Signaling Pathways.
Anticancer researchErlotinib Induces Cell Death by Blocking NIX-mediated Mitophagy Through Lysosomal Swelling in IDH1-mutant Cholangiocarcinoma.
Anticancer researchMitochondrial targets in IDH1-mutated cholangiocarcinoma.
Hepatology communicationsAssessing ChatGPT's role in patient education on cholangiocarcinoma: promise, pitfalls, and a call for validation.
European journal of gastroenterology & hepatologyImpact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.
Cancer research communicationsPreoperative prognostic model combining tumor burden score and tumor markers to predict long-term outcomes following hepatectomy for intrahepatic cholangiocarcinoma: a multi-institutional analysis.
Frontiers in oncologyMolecular Docking and MD Modeling Techniques for the Development of Novel ROS1 Kinase Inhibitors.
Pharmaceuticals (Basel, Switzerland)Stage-Dependent Metabolic Responses to Oral Nutritional Supplementation in Cancer Cachexia: A Single-Arm Pilot Study.
NutrientsAntimicrobial Activity of Aurisin A Against Streptococcus suis and Its Protective Effect on Epithelial Cells.
International journal of molecular sciencesTargeting Fatty Acids in Liver Cancer: Molecular Insights and Drug Approaches.
BiomoleculesThe Proximity of PD-1-CD103+ Tissue-Resident CD8+ T Cells to Tumor Cells Is Correlated with Improved Clinical Outcomes in Patients with Cholangiocarcinoma.
CancersTargeting Biliary Tract Cancers with Antibody-Drug Conjugates: Advances in Molecular Targets and Rational Combinations.
CancersUtility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.
Cancers[A Case of Hepatic Sclerosing Hemangioma Diagnosed as Intrahepatic Cholangiocarcinoma and Treated with Laparoscopic Posterior Segmentectomy].
Gan to kagaku ryoho. Cancer & chemotherapyPreoperative bilateral drainage for perihilar cholangiocarcinoma via endoscopic ultrasound-guided hepaticogastrostomy using a novel side-hole plastic stent.
EndoscopyCirc_0057105 promotes intrahepatic cholangiocarcinoma progression by sponging miR-1290 and regulating the MDM2/P53 pathway.
Cellular signallingSystemic treatment strategies for combined hepatocellular-cholangiocarcinoma: current evidence and future direction.
Journal of liver cancerMutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.
Cancer research communicationsThe rise of transplant oncology in primary liver cancer and metastatic disease.
Hepatology (Baltimore, Md.)ASO Visual Abstract: Is Extended Lymphadenectomy in Biliary Tract Cancers Justified? A Retrospective Comparative Study of Gallbladder Cancer, Perihilar and Intrahepatic Cholangiocarcinoma.
Annals of surgical oncologyPrognostic Value of Baseline Systemic Immune-Inflammation Index in Advanced Intrahepatic Cholangiocarcinoma Treated with First-Line Gemcitabine-Cisplatin Plus PD-L1 Inhibitor: A Single-Center Retrospective Study.
Current oncology (Toronto, Ont.)Clinicopathologic and Prognostic Differences Between LI-RADS M Targetoid and LI-RADS M Nontargetoid Observations: A Comparative Imaging-Based Study.
Journal of magnetic resonance imaging : JMRILength of Hospital Stay in Patients with Primary Liver Cancer Undergoing Surgery: Risk Factors and Predictive Model Development.
Journal of hepatocellular carcinomaIvosidenib for cholangiocarcinoma and acute myeloid leukaemia.
Australian prescriberCancer-Associated fibroblasts regulate the development of cholangiocarcinoma through IL-6/STAT3/AKR1C3 signaling axis.
Scientific reportsNeoadjuvant chemotherapy versus upfront surgery for perihilar cholangiocarcinoma: a propensity score matching analysis.
HPB : the official journal of the International Hepato Pancreato Biliary AssociationSurvival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Annals of transplantationAlterations of the oral mycobiome in patients with CCA.
BMC oral healthConcordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.
Signal transduction and targeted therapyA Cerebral Ethiodized Embolism after Lymphangiography: A Case Report and Literature Review.
Internal medicine (Tokyo, Japan)Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial.
BMJ openBronchobiliary Fistula Embolization in a Patient with Cholangiocarcinoma and Massive Bilioptysis.
Journal of vascular and interventional radiology : JVIRPercutaneous metallic stent placement for malignant extrahepatic biliary obstruction: single-center experience in 612 patients.
Acta radiologica (Stockholm, Sweden : 1987)IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse.
Frontiers in medicinePerihilar Extrahepatic Cholangiocarcinoma With Typical and Atypical Manifestations: Diagnostic Resolution During Autopsy.
CureusConfocal laser endomicroscopy improves diagnosis of cholangiocarcinoma: a case report and review.
Open life sciencesAccuracy of automated 3D biliary tract reconstruction compared to ERCP to assess Bismuth-Corlette classification in patients with perihilar cholangiocarcinoma.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverCaval reconstruction with autologous peritoneal patch as a strategy in complex hepatic resections.
Annals of hepato-biliary-pancreatic surgeryChanges in the 6th edition of the World Health Organization classification of tumours of the digestive system.
HistopathologyMultimodal CT for Predicting Microvascular Invasion in Solitary cHCC-CCA: Dual-Center External Validation.
Academic radiologyGlucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.
Diabetes research and clinical practiceDesign, synthesis and biological evaluation of (±)-kusunokinin derivatives as potent anticancer agents.
European journal of medicinal chemistryVPS33A Promotes Pemigatinib Resistance in Cholangiocarcinoma via Autophagy.
Digestive diseases and sciencesAn Unusual Presentation of Cholangiocarcinoma: The Sister Mary Joseph Nodule-A Case Report.
Reports (MDPI)Conserved Phosphoprotein Networks Identify Actionable Adhesion/Wnt and Metallothionein Modules in Cholangiocarcinoma.
Medical sciences (Basel, Switzerland)Advancements in intratumoral therapies for liver tumors.
Frontiers in oncology90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.
Journal of nuclear medicine : official publication, Society of Nuclear MedicineHepatocyte-targeted Bap1 reduction in the liver primes an inflammatory transcriptional response.
G3 (Bethesda, Md.)Relevance of Chemokines in Mobilizing γδ T Cells in the Biliary Tract Cancer Microenvironment: Potential for γδ T-Cell-Based Adoptive Cell Therapy.
American journal of clinical oncologyOutcome of resectable distal cholangiocarcinoma in a single-centre Western patient cohort: comparison of the 7th and 8th edition of the UICC/AJCC TNM classification.
Acta oncologica (Stockholm, Sweden)Oncogenic LPCAT1 Accelerates Intrahepatic Cholangiocarcinoma Development Through PI3K/Akt Signaling-Dependent Cell Cycle Regulation.
Journal of gastroenterology and hepatologyInterpretable ADC-based radiomics models for differentiating hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Frontiers in oncologyA Case of Preserving the Collateral Arterial Arcade in the Head of the Pancreas in a Patient with Celiac Axis Stenosis.
Yonago acta medicaHigh-resolution spatial multi-omics enables prognostic scoring in intrahepatic cholangiocarcinoma.
Molecular therapy : the journal of the American Society of Gene TherapySurgical Outcomes of Non-Benchmark Perihilar Cholangiocarcinoma: A Multicenter Study from High-Volume Centers in Japan.
Annals of surgeryPrognostic value of cGAS-STING-IRF3 signaling in cholangiocarcinoma patients.
PloS oneHepatic arterial infusion chemotherapy versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
International journal of surgery (London, England)Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology.
Oncology and therapyEstablish a streamlined molecular profiling workflow for the clinical management of advanced cholangiocarcinoma.
Journal of hepatologyS100A10 promotes glycolysis and malignant progression of CCA by activating the HK2/ERK signaling pathway.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoIs Extended Lymphadenectomy in Biliary Tract Cancers Justified? A Retrospective Comparative Study of Gallbladder Cancer, Perihilar and Intrahepatic Cholangiocarcinoma.
Annals of surgical oncologyRobotic portal lymphadenectomy for biliary tract cancers.
Updates in surgeryComprehensive analysis of disulfidptosis-related genes identifies clinically actionable prognostic biomarkers in cholangiocarcinoma.
Discover oncologyPatterns and risk factors of early recurrence after radical resection for intrahepatic cholangiocarcinoma.
World journal of gastrointestinal surgeryHepatic carcinosarcoma: a rare and aggressive case with unusual molecular signature!
Frontiers in oncologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Colangiocarcinoma.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Colangiocarcinoma
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Notch signaling in liver diseases: mechanistic insights and therapeutic implications.
- Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment.
- Artificial Intelligence in hepatology: A position paper by the Italian Association for the Study of the Liver.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver· 2026· PMID 41876274mais citado
- Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.
- The evolving role of futibatinib for advanced cholangiocarcinoma.
- Curative resection of borderline resectable perihilar cholangiocarcinoma following neoadjuvant gemcitabine and cisplatin plus durvalumab immunochemotherapy: a case report.
- Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma.
- Prospective Head-to-Head Comparison of Fibroblast Imaging with [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]FDG PET/CT in Unclear Hepatic Lesions.
- Lymph node dissection in intrahepatic cholangiocarcinoma: Cutting through heterogeneity to reveal the survival signal of an adequate dissection.
- [Differential diagnostics of inflammatory changes and epithelial neoplasia of extrahepatic bile ducts].
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:70567(Orphanet)
- MONDO:0019087(MONDO)
- GARD:9304(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
